Chemical inhibitors of CYP2D9 display a range of mechanisms by which they directly bind and inhibit the enzyme's activity. Quinidine, for instance, is a stereoisomer that targets the active site of CYP2D9, effectively preventing the metabolism of the enzyme's substrates by binding to the site where these reactions typically occur. Similarly, the antidepressant fluoxetine engages in competitive inhibition with CYP2D9, where it occupies the active site and competes with the natural substrates of the enzyme, thereby reducing the enzyme's ability to process these substrates. Paroxetine, another antidepressant, binds to the same critical active site on CYP2D9, leading to a decrease in the enzyme's metabolic activity by obstructing the site required for enzymatic function.
The impact of other inhibitors such as ajmalicine, an alkaloid, also involves the active site of CYP2D9, where it binds and prevents the enzyme from metabolizing its substrates. Amiodarone inhibits CYP2D9 by a similar mechanism, targeting the active site and thus interfering with the enzyme's normal function. Haloperidol, an antipsychotic, and ritonavir, a compound with antiviral properties, both inhibit CYP2D9 through direct interaction with the enzyme's active site, which in turn impedes the metabolic processing that CYP2D9 is responsible for. Antihistamines like diphenhydramine and chlorpheniramine inhibit CYP2D9 by binding to the active site and reducing the enzyme's ability to carry out its normal metabolic processes. Furthermore, bupropion and sertraline, both antidepressants, directly inhibit CYP2D9 by occupying its active site, thereby hindering the metabolic activity of the enzyme. Lastly, methadone, an opioid analgesic, binds to the active site of CYP2D9, acting as a blocker and therefore inhibiting the metabolic activity that would typically be facilitated by this enzyme. Each of these chemicals exhibits a specific inhibitory action on CYP2D9 by directly interacting with the enzyme's active site, which is pivotal for its metabolic function.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Quinidine | 56-54-2 | sc-212614 | 10 g | $102.00 | 3 | |
Quinidine is a stereoisomer of quinine that can inhibit CYP2D9 by binding to the enzyme's active site, thus preventing substrate metabolism. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $312.00 | 9 | |
Fluoxetine is an antidepressant known to inhibit CYP2D9 through competitive inhibition, where it directly competes with the enzyme's natural substrates for binding. | ||||||
Paroxetine | 61869-08-7 | sc-507527 | 1 g | $180.00 | ||
Paroxetine, another antidepressant, inhibits CYP2D9 by binding to the active site, which is critical for the enzyme's activity, thereby reducing its ability to metabolize its substrates. | ||||||
Amiodarone | 1951-25-3 | sc-480089 | 5 g | $312.00 | ||
Amiodarone can inhibit CYP2D9 by binding to the enzyme's active site, therefore obstructing the enzyme's normal metabolic activity. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Haloperidol is an antipsychotic that can inhibit CYP2D9 by directly interacting with the enzyme's active site, impeding the enzyme's ability to process substrates. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $122.00 | 7 | |
Ritonavir is known to inhibit CYP2D9 through direct interaction and binding with the enzyme's active site, which diminishes the enzyme's metabolic function. | ||||||
Diphenhydramine hydrochloride | 147-24-0 | sc-204729 sc-204729A sc-204729B | 10 g 25 g 100 g | $51.00 $82.00 $122.00 | 4 | |
Diphenhydramine is an antihistamine that can inhibit CYP2D9 by binding to the active site, which prevents the metabolism of substrates that the enzyme would normally process. | ||||||